Literature DB >> 32252803

Correction to: Physical exercise augmented cognitive behaviour therapy for older adults with generalised anxiety disorder (PEXACOG): study protocol for a randomized controlled trial.

Silje Haukenes Stavestrand1,2, Kristine Sirevåg3,4, Inger Hilde Nordhus3,5, Trond Sjøbø4, Trygve Bruun Endal4, Hans M Nordahl6,7, Karsten Specht3, Åsa Hammar3, Anne Halmøy8,9, Egil W Martinsen5,10, Eva Andersson11, Helene Hjelmervik3, Jan Mohlman12, Julian F Thayer13, Anders Hovland3,4.   

Abstract

Following the publication of our article [1], we have become aware of one error in the exclusion criteria, inconsistencies in Figure 1 and Figure 2, and a typo in the reference list.

Entities:  

Year:  2020        PMID: 32252803      PMCID: PMC7132867          DOI: 10.1186/s13063-020-04239-9

Source DB:  PubMed          Journal:  Trials        ISSN: 1745-6215            Impact factor:   2.279


Correction to: Trials (2019) 20:174 https://doi.org/10.1186/s13063-019-3268-9 Following the publication of our article [1], we have become aware of one error in the exclusion criteria, inconsistencies in Figs. 1 and 2, and a typo in the reference list.
Fig. 1

Study design. Visual presentation of the study design, including sample, assessments, and interventions. GAD, generalised anxiety disorder; CBT, cognitive behaviour therapy

Fig. 2

Standard protocol items: recommendation for interventional trials (SPIRIT) figure. Schedule of enrolment, interventions and assessments. Overview of the measures applied in the study. CBT, cognitive behaviour therapy; ADIS-IV, Anxiety Disorders Interview Schedule for DSM-IV; M.I.N.I., Mini International Neuropsychiatric Interview; PSWQ, Penn State Worry Questionnaire; GAD-7, Generalized Anxiety Disorder 7-item scale; IPAQ, International Physical Activity Questionnaire; HRV, heart rate variability; BDNF, brain-derived neurotropic factor; WASI, Wechsler Abbreviated Scale of Intelligence; WAIS-IV, Wechsler Adult Intelligence Scale – Fourth Edition; D-KEFS, Delis–Kaplan Executive Function System; TMT, Trail-Making Test; VF, Verbal Fluency; CWIT, Color Word Interference Test

Study design. Visual presentation of the study design, including sample, assessments, and interventions. GAD, generalised anxiety disorder; CBT, cognitive behaviour therapy Standard protocol items: recommendation for interventional trials (SPIRIT) figure. Schedule of enrolment, interventions and assessments. Overview of the measures applied in the study. CBT, cognitive behaviour therapy; ADIS-IV, Anxiety Disorders Interview Schedule for DSM-IV; M.I.N.I., Mini International Neuropsychiatric Interview; PSWQ, Penn State Worry Questionnaire; GAD-7, Generalized Anxiety Disorder 7-item scale; IPAQ, International Physical Activity Questionnaire; HRV, heart rate variability; BDNF, brain-derived neurotropic factor; WASI, Wechsler Abbreviated Scale of Intelligence; WAIS-IV, Wechsler Adult Intelligence Scale – Fourth Edition; D-KEFS, Delis–Kaplan Executive Function System; TMT, Trail-Making Test; VF, Verbal Fluency; CWIT, Color Word Interference Test Exclusion criterion # 10 is incorrect. Correction: (10) participating regularly in 60 min of moderate intensity physical exercise per week, divided across 2 or more bouts of physical exercise. The physical exercise exclusion criteria are omitted from Fig. 1 in the original publication. The correct version of Fig. 1 is included here. In Fig. 2, the interim testing contains three tests which are not conducted at this point of measure. These are The Five-Minute Pyramid test, The Biering-Sørensen Test, and the Dumbbell Arm Press Test. The correct version of Fig. 2 is included here. We have discovered a typo in the reference for the Expectancy / Credibility Scale. The correct reference is: Borkovec, T. D. and S. D. Nau (1972). “Credibility of analogue therapy rationales.” Journal of Behavior Therapy and Experimental Psychiatry 3(4): 257–260.
  1 in total

1.  Physical exercise augmented cognitive behaviour therapy for older adults with generalised anxiety disorder (PEXACOG): study protocol for a randomized controlled trial.

Authors:  Silje Haukenes Stavestrand; Kristine Sirevåg; Inger Hilde Nordhus; Trond Sjøbø; Trygve Bruun Endal; Hans M Nordahl; Karsten Specht; Åsa Hammar; Anne Halmøy; Egil W Martinsen; Eva Andersson; Helene Hjelmervik; Jan Mohlman; Julian F Thayer; Anders Hovland
Journal:  Trials       Date:  2019-03-18       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.